My Opera癌症与IGF-1(翻译自英国医学文献)
Tuesday, April 3, 2012 9:34:05 AM
布里斯托，英国。一些研究显示，血液中类胰岛素成长因子-I（insulin-like growth factor-I，IGF-1）的含量与结肠癌、前列腺癌和绝经前乳腺癌具有非常密切的关系。事实上，最近的证据表明，IGF-1高含量可能比前早期所报道的致癌的一些风险因素要重要的多。IGF-1是由人体生长激素所释放出来的，在胎儿和儿童的整个发育过程中能刺激胎儿和儿童的生长。IGF-1在人体中通常是与大蛋白质分子（IGF结合蛋白-3）紧紧结合在一起的，有证据表明，高水平的IDF结合蛋白-3能防止某些癌症的发展。
布里斯托大学的一个杰出的医学研究小组呼吁，应当对愈来愈多地使用IGF-1和生长激素的正在健美的人们和试图夺回青春的老年人引起关注。他们认为，IGF-1能够增加细胞的负荷和敏感性，从而使细胞发生癌变。他们还指出，最近的证据显示，IGF-1能阻止癌细胞的程序化死亡（凋亡，细胞程序性死亡(PCD)是一种由基因控制的、主动的细胞死亡过程）。研究人员警告说，人们使用生长激素和IGF-1促进剂是由于不太可能知道其潜在的危害。
制药业已经对IGF-1和癌症之间的关系理解得很清楚。阻止IGF-1的活性或提高IGF结合蛋白-3的活性的化疗药物正在研发过程中 。
Smith, George Davey, et al. Cancer and insulin-like growth factor-I（癌症与IGF-1）. British Medical Journal（英国医学杂志）, Vol. 321, October 7, 2000, pp. 847-48 (editorial)
国际健康新闻数据库
———————————————癌症与IGF-1分割线—————————————
英文原文：
IGF-1 and cancer
BRISTOL, UNITED KINGDOM. Several studies have shown powerful associations between blood levels of insulin-like growth factor-I (IGF-1) and the risk of colon cancer, prostate cancer, and premenopausal breast cancer. As a matter of fact, recent evidence indicates that high IGF-1 levels may be more important than other previously reported risk factors for cancer. IGF-1 is released by human growth hormone and stimulates growth throughout fetal and child development. IGF-1 in the body is normally tightly bound to a large protein molecule (IGF binding protein-3) and there is evidence that high levels of IGF binding protein-3 protect against the development of certain cancers.
A distinguished group of medical researchers at the University of Bristol now voice concern about the increasing use of IGF-1 and growth hormone enhancers by body builders and elderly people trying to recapture their vanishing youth. They suggest that IGF-1 may increase both cell turnover and the susceptibility of cells to become cancerous. They also point to recent evidence that indicates that IGF-1 prevents the programmed death (apoptosis) of cancer cells. The researchers warn that people using growth hormone and IGF-1 enhancers are unlikely to be aware of their potentially harmful effects.
The pharmaceutical industry is well aware of the increasingly clear association between IGF-1 and cancer. Chemotherapeutic drugs are being developed to block the activity of IGF-1 or enhance the activity of IGF binding protein-3.
Smith, George Davey, et al. Cancer and insulin-like growth factor-I. British Medical Journal, Vol. 321, October 7, 2000, pp. 847-48 (editorial)
布里斯托大学的一个杰出的医学研究小组呼吁，应当对愈来愈多地使用IGF-1和生长激素的正在健美的人们和试图夺回青春的老年人引起关注。他们认为，IGF-1能够增加细胞的负荷和敏感性，从而使细胞发生癌变。他们还指出，最近的证据显示，IGF-1能阻止癌细胞的程序化死亡（凋亡，细胞程序性死亡(PCD)是一种由基因控制的、主动的细胞死亡过程）。研究人员警告说，人们使用生长激素和IGF-1促进剂是由于不太可能知道其潜在的危害。
制药业已经对IGF-1和癌症之间的关系理解得很清楚。阻止IGF-1的活性或提高IGF结合蛋白-3的活性的化疗药物正在研发过程中 。
Smith, George Davey, et al. Cancer and insulin-like growth factor-I（癌症与IGF-1）. British Medical Journal（英国医学杂志）, Vol. 321, October 7, 2000, pp. 847-48 (editorial)
国际健康新闻数据库
———————————————癌症与IGF-1分割线—————————————
英文原文：
IGF-1 and cancer
BRISTOL, UNITED KINGDOM. Several studies have shown powerful associations between blood levels of insulin-like growth factor-I (IGF-1) and the risk of colon cancer, prostate cancer, and premenopausal breast cancer. As a matter of fact, recent evidence indicates that high IGF-1 levels may be more important than other previously reported risk factors for cancer. IGF-1 is released by human growth hormone and stimulates growth throughout fetal and child development. IGF-1 in the body is normally tightly bound to a large protein molecule (IGF binding protein-3) and there is evidence that high levels of IGF binding protein-3 protect against the development of certain cancers.
A distinguished group of medical researchers at the University of Bristol now voice concern about the increasing use of IGF-1 and growth hormone enhancers by body builders and elderly people trying to recapture their vanishing youth. They suggest that IGF-1 may increase both cell turnover and the susceptibility of cells to become cancerous. They also point to recent evidence that indicates that IGF-1 prevents the programmed death (apoptosis) of cancer cells. The researchers warn that people using growth hormone and IGF-1 enhancers are unlikely to be aware of their potentially harmful effects.
The pharmaceutical industry is well aware of the increasingly clear association between IGF-1 and cancer. Chemotherapeutic drugs are being developed to block the activity of IGF-1 or enhance the activity of IGF binding protein-3.
Smith, George Davey, et al. Cancer and insulin-like growth factor-I. British Medical Journal, Vol. 321, October 7, 2000, pp. 847-48 (editorial)
